CL2017001718A1 - Derivados de glucagón con estabilidad mejorada - Google Patents
Derivados de glucagón con estabilidad mejoradaInfo
- Publication number
- CL2017001718A1 CL2017001718A1 CL2017001718A CL2017001718A CL2017001718A1 CL 2017001718 A1 CL2017001718 A1 CL 2017001718A1 CL 2017001718 A CL2017001718 A CL 2017001718A CL 2017001718 A CL2017001718 A CL 2017001718A CL 2017001718 A1 CL2017001718 A1 CL 2017001718A1
- Authority
- CL
- Chile
- Prior art keywords
- glucagon
- improved stability
- hypoglucemia
- prevention
- accordance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A UN NUEVO PÉPTIDO DERIVADO DEL GLUCAGÓN Y A UNA COMPOSICIÓN PARA LA PREVENCIÓN O EL TRATAMIENTO DE HIPOGLUCEMIA, QUE CONTIENE EL NUEVO PÉPTIDO DERIVADO DEL GLUCAGÓN COMO PRINCIPIO ACTIVO. EL DERIVADO DE GLUCAGÓN DE ACUERDO CON LA PRESENTE INVENCIÓN TIENE PROPIEDADES FÍSICAS MEJORADAS DEBIDO AL CAMBIO EN EL PUNTO ISOELÉCTRICO (PI) MIENTRAS QUE ES CAPAZ DE MANTENER UNA ACTIVIDAD EN LOS RECEPTORES DEL GLUCAGÓN Y, POR TANTO, PUEDE MEJORAR LA CONFORMIDAD DEL PACIENTE CUANDO SE USA COMO UN AGENTE HIPOGLUCÉMICO Y TAMBIÉN ES ADECUADO PARA LA ADMINISTRACIÓN EN COMBINACIÓN CON OTROS AGENTES ANTIOBESIDAD. POR CONSIGUIENTE, EL DERIVADO DE GLUCAGÓN DE ACUERDO CON LA PRESENTE INVENCIÓN SE PUEDE USAR DE MANERA EFICAZ PARA LA PREVENCIÓN Y EL TRATAMIENTO DE LA HIPOGLUCEMIA Y LA OBESIDAD.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140193800 | 2014-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001718A1 true CL2017001718A1 (es) | 2018-01-12 |
Family
ID=56284642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001718A CL2017001718A1 (es) | 2014-12-30 | 2017-06-28 | Derivados de glucagón con estabilidad mejorada |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11135271B2 (es) |
| EP (2) | EP3241841A4 (es) |
| JP (2) | JP6797122B2 (es) |
| KR (1) | KR102291020B1 (es) |
| CN (1) | CN107636009B (es) |
| AR (1) | AR103322A1 (es) |
| AU (1) | AU2015372818A1 (es) |
| CA (1) | CA2972748A1 (es) |
| CL (1) | CL2017001718A1 (es) |
| CO (1) | CO2017006308A2 (es) |
| CR (1) | CR20170293A (es) |
| DO (1) | DOP2017000156A (es) |
| EA (1) | EA035527B1 (es) |
| EC (1) | ECSP17040923A (es) |
| GT (1) | GT201700150A (es) |
| HK (1) | HK1248713A1 (es) |
| IL (2) | IL253206B (es) |
| MA (1) | MA40709B1 (es) |
| MX (1) | MX2017008569A (es) |
| MY (1) | MY185334A (es) |
| NZ (1) | NZ733464A (es) |
| PE (2) | PE20230304A1 (es) |
| PH (1) | PH12017501222A1 (es) |
| SG (1) | SG11201705376SA (es) |
| TN (1) | TN2017000271A1 (es) |
| TW (1) | TW201639878A (es) |
| UA (1) | UA126960C2 (es) |
| WO (1) | WO2016108586A1 (es) |
| ZA (1) | ZA201705015B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11135271B2 (en) | 2014-12-30 | 2021-10-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives with improved stability |
| US10696725B2 (en) | 2015-06-30 | 2020-06-30 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| MX2018008027A (es) | 2015-12-31 | 2018-11-29 | Hanmi Pharm Ind Co Ltd | Activador triple que activa receptor de glucagon, glp-1 y gip. |
| CA3029518A1 (en) * | 2016-06-29 | 2018-01-04 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof |
| AU2018215840A1 (en) | 2017-02-03 | 2019-08-01 | Hanmi Pharm. Co., Ltd. | Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof |
| NZ765453A (en) * | 2017-12-22 | 2024-03-22 | Hanmi Pharmaceutical Co Ltd | Therapeutic enzyme fusion protein having novel structure and use thereof |
| MX2020007768A (es) * | 2018-01-23 | 2020-11-12 | Xeris Pharmaceuticals Inc | Tratamiento contra hipoglucemia posbariátrica usando pequeñas dosis de glucagón estable. |
| JP2022514835A (ja) * | 2018-12-21 | 2022-02-16 | ハンミ ファーマシューティカル カンパニー リミテッド | インスリン及びグルカゴンを含む薬学組成物 |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| JP2023526551A (ja) | 2020-05-22 | 2023-06-21 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン誘導体の持続型結合体の液状製剤 |
| EP4183407A1 (en) | 2020-07-15 | 2023-05-24 | Hanmi Pharm. Co., Ltd. | Therapeutic use of glucagon derivative or conjugate thereof for liver disease |
| EP4321170A1 (en) | 2021-04-09 | 2024-02-14 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating chronic kidney disease containing glucagon derivative |
| KR20230095666A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 물질 및 이의 용도 |
| CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| GB9423277D0 (en) | 1994-11-18 | 1995-01-11 | Univ Nottingham | Pulsed laser deposition of coatings |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| AU2002317599B2 (en) | 2001-07-31 | 2008-04-03 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
| WO2004093823A2 (en) | 2003-03-19 | 2004-11-04 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| ATE522548T1 (de) | 2003-11-13 | 2011-09-15 | Hanmi Holdings Co Ltd | Verfahren zur massenproduktion der konstanten region von immunglobulin |
| MX2008013304A (es) | 2006-04-20 | 2008-10-27 | Amgen Inc | Compuestos de peptido 1 tipo glucagon. |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| EP2124974B1 (en) | 2007-01-05 | 2017-03-15 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| EP2111414B1 (en) | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
| SG178797A1 (en) | 2007-06-19 | 2012-03-29 | Otsuka Chemical Co Ltd | Oligosaccharide chain added glp-1 peptide |
| WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| KR20110039230A (ko) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
| US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
| WO2010096052A1 (en) * | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| MX2011013625A (es) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip. |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
| NZ601167A (en) | 2010-01-20 | 2014-12-24 | Zealand Pharma As | Treatment of cardiac conditions |
| EP2552950A1 (en) * | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
| EP2568993A4 (en) | 2010-05-13 | 2014-02-19 | Univ Indiana Res & Tech Corp | GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| PE20140186A1 (es) | 2010-12-22 | 2014-02-13 | Univ Indiana Res & Tech Corp | Analogos de glucagon que presentan actividad de receptor de gip |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| US10471127B2 (en) | 2011-05-18 | 2019-11-12 | Mederis Diabetes, Llc | Peptide pharmaceuticals for insulin resistance |
| SG195258A1 (en) * | 2011-06-10 | 2013-12-30 | Hanmi Science Co Ltd | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
| PE20181268A1 (es) * | 2011-06-17 | 2018-08-03 | Hanmi Science Co Ltd | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y el uso del mismo |
| US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
| KR20140097151A (ko) * | 2011-11-17 | 2014-08-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
| CA2877127A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Analogs of glucagon exhibiting gip receptor activity |
| JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Ｇｉｐ受容体活性を示すグルカゴンアナローグ |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| AR093387A1 (es) | 2012-11-06 | 2015-06-03 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de proteina que comprende oxintomodulina y un fragmento de inmunoglobulina |
| US11065304B2 (en) | 2012-11-20 | 2021-07-20 | Mederis Diabetes, Llc | Peptide pharmaceuticals for insulin resistance |
| ES2906975T3 (es) | 2012-11-20 | 2022-04-21 | Eumederis Pharmaceuticals Inc | Productos farmacéuticos de péptidos mejorados |
| JP2016503771A (ja) | 2012-12-21 | 2016-02-08 | サノフイ | エキセンジン−４誘導体 |
| AU2014255608B2 (en) * | 2013-04-18 | 2018-01-25 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
| EP3033355A1 (en) | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| US11135271B2 (en) | 2014-12-30 | 2021-10-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives with improved stability |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| US10696725B2 (en) * | 2015-06-30 | 2020-06-30 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| MX2018008027A (es) | 2015-12-31 | 2018-11-29 | Hanmi Pharm Ind Co Ltd | Activador triple que activa receptor de glucagon, glp-1 y gip. |
-
2015
- 2015-12-30 US US15/540,729 patent/US11135271B2/en active Active
- 2015-12-30 KR KR1020150189532A patent/KR102291020B1/ko active IP Right Grant
- 2015-12-30 MA MA40709A patent/MA40709B1/fr unknown
- 2015-12-30 UA UAA201707040A patent/UA126960C2/uk unknown
- 2015-12-30 EA EA201791333A patent/EA035527B1/ru not_active IP Right Cessation
- 2015-12-30 MX MX2017008569A patent/MX2017008569A/es unknown
- 2015-12-30 NZ NZ733464A patent/NZ733464A/en unknown
- 2015-12-30 SG SG11201705376SA patent/SG11201705376SA/en unknown
- 2015-12-30 TW TW104144427A patent/TW201639878A/zh unknown
- 2015-12-30 TN TN2017000271A patent/TN2017000271A1/en unknown
- 2015-12-30 AU AU2015372818A patent/AU2015372818A1/en not_active Abandoned
- 2015-12-30 CA CA2972748A patent/CA2972748A1/en active Pending
- 2015-12-30 WO PCT/KR2015/014422 patent/WO2016108586A1/ko active Application Filing
- 2015-12-30 EP EP15875680.9A patent/EP3241841A4/en not_active Withdrawn
- 2015-12-30 MY MYPI2017000967A patent/MY185334A/en unknown
- 2015-12-30 CN CN201580077186.3A patent/CN107636009B/zh active Active
- 2015-12-30 AR ARP150104340A patent/AR103322A1/es unknown
- 2015-12-30 EP EP19172184.4A patent/EP3575314B1/en active Active
- 2015-12-30 CR CR20170293A patent/CR20170293A/es unknown
- 2015-12-30 PE PE2022001996A patent/PE20230304A1/es unknown
- 2015-12-30 PE PE2017001168A patent/PE20171154A1/es unknown
- 2015-12-30 JP JP2017535417A patent/JP6797122B2/ja active Active
-
2017
- 2017-06-27 IL IL253206A patent/IL253206B/en unknown
- 2017-06-27 CO CONC2017/0006308A patent/CO2017006308A2/es unknown
- 2017-06-28 CL CL2017001718A patent/CL2017001718A1/es unknown
- 2017-06-28 GT GT201700150A patent/GT201700150A/es unknown
- 2017-06-28 EC ECIEPI201740923A patent/ECSP17040923A/es unknown
- 2017-06-29 DO DO2017000156A patent/DOP2017000156A/es unknown
- 2017-06-29 PH PH12017501222A patent/PH12017501222A1/en unknown
- 2017-07-24 ZA ZA2017/05015A patent/ZA201705015B/en unknown
-
2018
- 2018-04-10 HK HK18104685.2A patent/HK1248713A1/zh unknown
-
2020
- 2020-08-28 JP JP2020144259A patent/JP7079301B2/ja active Active
-
2021
- 2021-03-09 IL IL281375A patent/IL281375B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001718A1 (es) | Derivados de glucagón con estabilidad mejorada | |
| CL2018000684A1 (es) | Moduladores de la proteína de núcleo de la hepatitis b. | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CL2016002269A1 (es) | Moduladores alostéricos del núcleo proteico de la hepatitis b. | |
| CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
| CL2016000952A1 (es) | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2018000978A1 (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
| CL2017000999A1 (es) | Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| CL2017001438A1 (es) | Antagonistas de miostatina o activina para el tratamiento de sarcopenia | |
| UY36342A (es) | Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos | |
| UY36179A (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagón | |
| CR20160367A (es) | Compuesto heterocíclico fusionado | |
| CL2013003019A1 (es) | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. | |
| CL2015002698A1 (es) | Nuevos compuestos y composiciones para la inhibicion de fasn | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| CR20180495A (es) | Deribados de indol sustituidos como inhibidores de replicación viral del dengue | |
| CL2017002031A1 (es) | Formulación en polvo nasal para el tratamiento de hipoglicemia | |
| DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
| CL2017001904A1 (es) | Composición para el tratamiento de enfermedad veno-oclusiva hepática. | |
| EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
| DOP2017000146A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| EA201891783A1 (ru) | Композиция для растворения аморфных дитиазинов и способ ее применения | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo |